

---

FOR PUBLIC RELEASE

NZX Limited  
Wellington

20 October 2026

### **Rua Bioscience Rights Offer raises approximately \$1.0 million**

Rua Bioscience Limited (NZX: RUA) confirms that its 1 for 3 renounceable Rights Offer, at an issue price of \$0.025 per new share, closed on 15 October 2026, raising approximately \$1.0 million.

The amount raised comprises entitlements and oversubscriptions taken up by existing shareholders. Eligible shareholders subscribed for 39,648,249 new shares, including oversubscriptions which is approximately 12% of the existing shares.

Rua will now allow applications for the remaining shortfall shares in accordance with NZX Listing Rule 4.4.

The allotment and issue of, and trading in, new shares under the Rights Offer is expected to occur on Wednesday 21 October 2026.

Rua Bioscience Chair Anna Stove said: "On behalf of the Board and the Rua Bioscience team, I want to thank the shareholders who participated in the Rights Offer. The approximately \$1.0 million raised provides additional capital to support Rua's growth, but is below the \$2.8 million sought and does not fully meet the company's working capital requirements."

"Rua has a significant commercial opportunity ahead. Our UK sales and distribution agreement is expected to generate more than NZ\$10 million in revenue over a two-year term. It is our largest export agreement to date and a significant milestone for a company of Rua's size, demonstrating the potential of our export-led, capital-light model."

"Delivering on this opportunity requires us to fund inventory and working capital ahead of sales. Our principal constraint is working capital, not infrastructure. The Board remains confident that Rua can secure the additional capital required. We are in discussions with existing shareholders who wanted to see the Rights Offer outcome before considering further commitments. Subject to shareholder approval at the ASM, placement capacity would provide another funding option. We are also pursuing options to realise value from the Gisborne manufacturing facility."

**ENDS**

The person who authorised this announcement:

Paul Naske  
Chief Executive Officer  
[paul.naske@ruabio.com](mailto:paul.naske@ruabio.com)  
+64 21 445154